Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) EBIT Margin (2024 - 2026)

Prelude Therapeutics' EBIT Margin history spans 3 years, with the latest figure at 309.54% for Q1 2026.

  • On a quarterly basis, EBIT Margin changed N/A to 309.54% in Q1 2026 year-over-year; TTM through Mar 2026 was 503.21%, a N/A change, with the full-year FY2025 number at 861.33%, up 113458.0% from a year prior.
  • EBIT Margin hit 309.54% in Q1 2026 for Prelude Therapeutics, down from 307.59% in the prior quarter.
  • Over the last five years, EBIT Margin for PRLD hit a ceiling of 307.59% in Q4 2025 and a floor of 1145.87% in Q3 2024.
  • Historically, EBIT Margin has averaged 584.58% across 3 years, with a median of 314.12% in 2025.
  • The widest YoY moves for EBIT Margin: up 83174bps in 2025, down 53819bps in 2025.
  • Tracing PRLD's EBIT Margin over 3 years: stood at 845.78% in 2024, then surged by 64bps to 307.59% in 2025, then fell by -1bps to 309.54% in 2026.
  • Business Quant data shows EBIT Margin for PRLD at 309.54% in Q1 2026, 307.59% in Q4 2025, and 314.12% in Q3 2025.